AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LUMOS DIAGNOSTICS HOLDINGS L

0.265

-0.010-3.64%

Volume:1.11M

Turnover:299.64K

Market Cap:210.00M

PE:-17.74

High:0.275

Open:0.275

Low:0.265

Close:0.275

52wk High:0.330

52wk Low:0.019

Shares:792.45M

Float Shares:375.60M

Volume Ratio:0.63

T/O Rate:0.29%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.015

EPS(LYR):-0.015

ROE:-108.29%

ROA:-21.17%

PB:24.20

PE(LYR):-17.80

Loading ...

Overview Company News Filings

BRIEF-Lumos Diagnostics Posts Qtrly Unaudited Revenue of $2.7 Million

Lumos Diagnostics - Unaudited Revenue of US$2.7 Mln for the Quarter

THOMSON REUTERS

Lumos Diagnostics Holdings Limited (ASX:LDX) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Simply Wall St.

BRIEF-Lumos Diagnostics Secures Follow On Contract With Aptatek

Lumos Diagnostics Secures Follow-On Contract to Manage Study to Advance In-Home Phenylketonuria Monitoring Device to Support US FDA Clearance

MT Newswires Live

Lumos Diagnostics - Contract Valued at About US$0.4 Mln

THOMSON REUTERS

Lumos Diagnostics Holdings Ltd-Lumos Secures Follow on Contract With Aptatek

THOMSON REUTERS

Lumos Agrees With Medical Distributor for Sale of Respiratory Test Across the Baltic Region

MT Newswires Live

BRIEF-Lumos Diagnostics Secures Distribution For Febridx In Baltic Region

Lumos Diagnostics Holdings Ltd - Lumos Secures Distribution for Febridx in Baltic Region

THOMSON REUTERS

ASX Penny Stocks With Market Caps Under A$300M To Consider

Simply Wall St.

Market Participants Recognise Lumos Diagnostics Holdings Limited's (ASX:LDX) Revenues Pushing Shares 37% Higher

Simply Wall St.

Lumos Secures US Medicare Reimbursement Recognition for Respiratory Test from All Administrative Contractors; Shares Rise 13%

MT Newswires Live

Lumos Diagnostics Holdings Ltd-Lumos Secures 100% US Medicare Reimbursement for Febridx

THOMSON REUTERS

Lumos Diagnostics Partners with US Medical Technology Firm to Support US Commercialization; Shares Up 12%

MT Newswires Live

BRIEF-Lumos Diagnostics Enters Strategic Collaboration With AcuityMD

Lumos Diagnostics - Enters Strategic Collaboration With Acuitymd to Support U.S. Commercialization of Febridx Test

THOMSON REUTERS

ASX Midday Sector Update: Information Technology Stocks Rise, Healthcare Sector Declines

MT Newswires Live

BUZZ-Australia's Lumos Diagnostics hits 3-1/2-year high on sales jump

BRIEF-Lumos Diagnostics Reports Q1 Revenue Of $3.4 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LDX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LDX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"LDX.AU\",,,,,undefined,":{"symbol":"LDX.AU","market":"AU","secType":"STK","nameCN":"LUMOS DIAGNOSTICS HOLDINGS L","latestPrice":0.265,"timestamp":1770775341831,"preClose":0.275,"halted":0,"volume":1107117,"delay":0,"changeRate":-0.03636363636363639,"nameEN":"LUMOS DIAGNOSTICS HOLDINGS L","floatShares":375602340,"shares":792445496,"eps":-0.014938478668376769,"marketStatus":"Trading","change":-0.01,"latestTime":"02-11 13:07:01 AEDT","open":0.275,"high":0.275,"low":0.265,"amount":299640,"amplitude":0.036364,"askPrice":0.27,"askSize":258159,"bidPrice":0.265,"bidSize":267497,"shortable":3,"etf":0,"ttmEps":-0.014938478668376769,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770786000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.275,"openAndCloseTimeList":[[1770764400000,1770786000000]],"volumeRatio":0.6312,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"LDX.AU\",,,,,undefined,":{"symbol":"LDX.AU","floatShares":375602340,"roa":"-21.17%","roe":"-108.29%","lyrEps":-0.014884,"volumeRatio":0.6312,"shares":792445496,"dividePrice":0,"high":0.275,"amplitude":0.036364,"preClose":0.275,"low":0.265,"week52Low":0.019,"pbRate":"24.20","psRate":"12.02","week52High":0.33,"institutionHeld":0,"latestPrice":0.265,"committee":0.017764,"eps":-0.014938478668376769,"divideRate":0,"volume":1107117,"delay":0,"ttmEps":-0.014938478668376769,"open":0.275,"prevYearClose":0.285,"prevWeekClose":0.235,"prevMonthClose":0.215,"prevQuarterClose":0.285,"fiveDayClose":0.27,"twentyDayClose":0.285,"sixtyDayClose":0.2,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LDX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-08-28","symbol":"LDX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756339200000,"name":null,"time":"","dateTimestamp":1756303200000,"actualEps":null},{"date":"2024-07-31","symbol":"LDX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722384000000,"name":null,"time":"","dateTimestamp":1722348000000,"actualEps":null},{"date":"2024-02-28","symbol":"LDX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1709074800000,"name":null,"time":"","dateTimestamp":1709038800000,"actualEps":null},{"market":"AU","date":"2023-08-30","symbol":"LDX.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1693317600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LDX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LDX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607086197","title":"BRIEF-Lumos Diagnostics Posts Qtrly Unaudited Revenue of $2.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2607086197","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607086197?lang=en_us&edition=fundamental","pubTime":"2026-01-29 14:41","pubTimestamp":1769668895,"startTime":"0","endTime":"0","summary":"BRIEF-Lumos Diagnostics Posts Qtrly Unaudited Revenue of $2.7 Million Jan 29 (Reuters) - Lumos Diagnostics Holdings Ltd LDX.AX:UNAUDITED REVENUE OF US$2.7 MILLION FOR THE QUARTERFurther company coverage: LDX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YT1AG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7126","LDX.AU"],"gpt_icon":0},{"id":"2607764307","title":"Lumos Diagnostics - Unaudited Revenue of US$2.7 Mln for the Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2607764307","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607764307?lang=en_us&edition=fundamental","pubTime":"2026-01-29 11:23","pubTimestamp":1769657019,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YT1AG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7126","LDX.AU"],"gpt_icon":0},{"id":"2606751205","title":"Lumos Diagnostics Holdings Limited (ASX:LDX) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing","url":"https://stock-news.laohu8.com/highlight/detail?id=2606751205","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606751205?lang=en_us&edition=fundamental","pubTime":"2026-01-28 04:33","pubTimestamp":1769546003,"startTime":"0","endTime":"0","summary":"Lumos Diagnostics Holdings Limited ( ASX:LDX ) shareholders won't be pleased to see that the share price has had a very...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-ldx/lumos-diagnostics-holdings-shares/news/lumos-diagnostics-holdings-limited-asxldx-stocks-pounded-by","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-ldx/lumos-diagnostics-holdings-shares/news/lumos-diagnostics-holdings-limited-asxldx-stocks-pounded-by","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7126","LDX.AU"],"gpt_icon":0},{"id":"2604990149","title":"BRIEF-Lumos Diagnostics Secures Follow On Contract With Aptatek","url":"https://stock-news.laohu8.com/highlight/detail?id=2604990149","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604990149?lang=en_us&edition=fundamental","pubTime":"2026-01-19 11:29","pubTimestamp":1768793379,"startTime":"0","endTime":"0","summary":"BRIEF-Lumos Diagnostics Secures Follow On Contract With AptatekJan 19 (Reuters) - Lumos Diagnostics Holdings Ltd LDX.AX:LUMOS SECURES FOLLOW ON CONTRACT WITH APTATEKCONTRACT VALUED AT ABOUT US$0.4 MILLIONFurther company coverage: LDX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nTUE6TVWJT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7126","LDX.AU"],"gpt_icon":0},{"id":"2604903283","title":"Lumos Diagnostics Secures Follow-On Contract to Manage Study to Advance In-Home Phenylketonuria Monitoring Device to Support US FDA Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2604903283","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604903283?lang=en_us&edition=fundamental","pubTime":"2026-01-19 09:10","pubTimestamp":1768785015,"startTime":"0","endTime":"0","summary":"Lumos Diagnostics Holdings  secured a follow-on contract with Aptatek Biosciences to manage the institutional review board-approved multi-center study to advance an in-home monitoring tool for the screening and management of phenylketonuria to support clearance from the US Food and Drug Administration, according to a Monday Australian bourse filing.Lumos will provide clinical study support services, from startup through to close-out, including compilation and statistical analysis of the results and generation of the clinical study report for submission to the US FDA. The study is expected to start in the second quarter and run for around six months.This new contract is valued at around $400,000, which will be charged on a time-and-materials basis.The firm's shares rose 2% in recent trading on Monday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4211","HBCP","LDX.AU","BK7126","BK4195"],"gpt_icon":0},{"id":"2604970175","title":"Lumos Diagnostics - Contract Valued at About US$0.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2604970175","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604970175?lang=en_us&edition=fundamental","pubTime":"2026-01-19 07:48","pubTimestamp":1768780096,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260118:nTUE6TVWJT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7126","LDX.AU"],"gpt_icon":0},{"id":"2604176970","title":"Lumos Diagnostics Holdings Ltd-Lumos Secures Follow on Contract With Aptatek","url":"https://stock-news.laohu8.com/highlight/detail?id=2604176970","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604176970?lang=en_us&edition=fundamental","pubTime":"2026-01-19 07:48","pubTimestamp":1768780096,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260118:nTUE6TVWJT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7126","LDX.AU"],"gpt_icon":0},{"id":"2592242939","title":"Lumos Agrees With Medical Distributor for Sale of  Respiratory Test Across the Baltic Region","url":"https://stock-news.laohu8.com/highlight/detail?id=2592242939","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592242939?lang=en_us&edition=fundamental","pubTime":"2025-12-18 13:44","pubTimestamp":1766036651,"startTime":"0","endTime":"0","summary":"Lumos Diagnostics Holdings  agreed with Interlux Group for the sale of the company's point-of-care respiratory test, FebriDx, across the Baltic region, according to a Thursday filing with the Australian bourse.Interlux will be responsible for the sale, distribution, and inventory management of FebriDx, and has placed an initial stocking order to support its immediate availability across the region, the filing said.Shares of the company rose 4% on market close.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7126","LDX.AU"],"gpt_icon":0},{"id":"2592194033","title":"BRIEF-Lumos Diagnostics Secures Distribution For Febridx In Baltic Region","url":"https://stock-news.laohu8.com/highlight/detail?id=2592194033","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592194033?lang=en_us&edition=fundamental","pubTime":"2025-12-18 09:22","pubTimestamp":1766020929,"startTime":"0","endTime":"0","summary":"BRIEF-Lumos Diagnostics Secures Distribution For Febridx In Baltic RegionDec 18 (Reuters) - Lumos Diagnostics Holdings Ltd LDX.AX:LUMOS SECURES DISTRIBUTION FOR FEBRIDX IN BALTIC REGIONFurther company coverage: LDX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XN19O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7126","LDX.AU"],"gpt_icon":0},{"id":"2592980947","title":"Lumos Diagnostics Holdings Ltd - Lumos Secures Distribution for Febridx in Baltic Region","url":"https://stock-news.laohu8.com/highlight/detail?id=2592980947","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592980947?lang=en_us&edition=fundamental","pubTime":"2025-12-18 09:08","pubTimestamp":1766020081,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XN19O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7126","LDX.AU"],"gpt_icon":0},{"id":"2591603872","title":"ASX Penny Stocks With Market Caps Under A$300M To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=2591603872","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591603872?lang=en_us&edition=fundamental","pubTime":"2025-12-16 10:05","pubTimestamp":1765850707,"startTime":"0","endTime":"0","summary":"The Australian market is experiencing a period of uncertainty, with shares opening flat and lacking the anticipated end-of-year rally. Despite this cautious atmosphere, there are still opportunities for investors to explore, particularly in the realm of penny stocks. Although the term \"penny stocks\" may seem outdated, these smaller or newer companies can offer intriguing prospects for those willing to look beyond larger firms.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-ldx/lumos-diagnostics-holdings-shares/news/asx-penny-stocks-with-market-caps-under-a300m-to-consider","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-ldx/lumos-diagnostics-holdings-shares/news/asx-penny-stocks-with-market-caps-under-a300m-to-consider","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7132","BK7012","MTO.AU","BK4563","BK4526","VRS.AU","BK7111","BK4509","EDU.AU","BK7077","LU2242644610.SGD","WAF.AU","GWA.AU","BK4585","BK4588","BK7128","BK7045","IGL.AU","EZZ.AU","LU0455707207.USD","AAL.AU","BK7143","LU0048580855.USD","BK4531","LU0823426480.USD","SSM.AU","BK4204","LU0823426308.USD","DSK.AU","BK4535","LDX.AU","LU0502904849.HKD","BK4506","BK7055","BK7506","LU0572944931.SGD","LU0359201612.USD","BK7048","LU1023057109.AUD","BK4505","WHI.AU","BK4503","BK7126","LU0359202008.SGD","BK7104","LU0327786744.USD","BK4510","LU0370786039.SGD","BK7050"],"gpt_icon":0},{"id":"2589383940","title":"Market Participants Recognise Lumos Diagnostics Holdings Limited's (ASX:LDX) Revenues Pushing Shares 37% Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2589383940","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589383940?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:15","pubTimestamp":1765149339,"startTime":"0","endTime":"0","summary":"Despite an already strong run, Lumos Diagnostics Holdings Limited ( ASX:LDX ) shares have been powering on, with a gain...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-ldx/lumos-diagnostics-holdings-shares/news/market-participants-recognise-lumos-diagnostics-holdings-lim","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-ldx/lumos-diagnostics-holdings-shares/news/market-participants-recognise-lumos-diagnostics-holdings-lim","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LDX.AU"],"gpt_icon":0},{"id":"2585519659","title":"Lumos Secures US Medicare Reimbursement Recognition for Respiratory Test from All Administrative Contractors; Shares Rise 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585519659","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585519659?lang=en_us&edition=fundamental","pubTime":"2025-11-21 12:47","pubTimestamp":1763700445,"startTime":"0","endTime":"0","summary":"Lumos Diagnostics Holdings  has received Medicare reimbursement recognition for the company's point-of-care respiratory test, FebriDx, from US Medicare administrative contractor  National Government Services, at a rate of $41.38 per test, according to a Friday filing with the Australian bourse.The company has now achieved coverage from all seven MACs, and will now work with them to establish a formal written policy, the filing said.Shares of the company rose 13% in recent Friday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4231","BK4080","LDX.AU","BK4551","MAC.AU","BK7126","MAC","BK7110"],"gpt_icon":0},{"id":"2585167708","title":"Lumos Diagnostics Holdings Ltd-Lumos Secures 100% US Medicare Reimbursement for Febridx","url":"https://stock-news.laohu8.com/highlight/detail?id=2585167708","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585167708?lang=en_us&edition=fundamental","pubTime":"2025-11-21 10:18","pubTimestamp":1763691483,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUEBLRSQ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LDX.AU","BK7126"],"gpt_icon":0},{"id":"2584080389","title":"Lumos Diagnostics Partners with US Medical Technology Firm to Support US Commercialization; Shares Up 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584080389","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584080389?lang=en_us&edition=fundamental","pubTime":"2025-11-20 09:34","pubTimestamp":1763602475,"startTime":"0","endTime":"0","summary":"Lumos Diagnostics  partnered with AcuityMD to support the US commercialization of its FebriDx test through enhanced visibility into reimbursement performance under the Proprietary Laboratory Analyses Code #0442U, according to a Thursday filing with the Australian bourse.AcuityMD will use its artificial intelligence-enabled platform to work with the company's US commercial collaborator, PRO-spectus, to analyze data from patients to ensure field efforts are leading to the desired reimbursement and repeat business outcomes for FebriDx, the filing said.Lumos Diagnostics shares rose 12% in midday trade on Thursday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7126","LDX.AU"],"gpt_icon":0},{"id":"2584081819","title":"BRIEF-Lumos Diagnostics Enters Strategic Collaboration With AcuityMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2584081819","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584081819?lang=en_us&edition=fundamental","pubTime":"2025-11-20 09:21","pubTimestamp":1763601719,"startTime":"0","endTime":"0","summary":"BRIEF-Lumos Diagnostics Enters Strategic Collaboration With AcuityMD Nov 20 (Reuters) - Lumos Diagnostics Holdings Ltd LDX.AX:ENTERS STRATEGIC COLLABORATION WITH ACUITYMD TO SUPPORT U.S. COMMERCIALIZATION OF FEBRIDX TESTFurther company coverage: LDX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nFWN3WV12E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LDX.AU","BK7126"],"gpt_icon":0},{"id":"2584763389","title":"Lumos Diagnostics - Enters Strategic Collaboration With Acuitymd to Support U.S. Commercialization of Febridx Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2584763389","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584763389?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:31","pubTimestamp":1763587879,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV12E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7126","LDX.AU"],"gpt_icon":0},{"id":"2577573775","title":"ASX Midday Sector Update: Information Technology Stocks Rise, Healthcare Sector Declines","url":"https://stock-news.laohu8.com/highlight/detail?id=2577573775","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577573775?lang=en_us&edition=fundamental","pubTime":"2025-10-24 10:40","pubTimestamp":1761273613,"startTime":"0","endTime":"0","summary":"Information technology stocks advanced over 1% at midday Monday.Overnight, the Nasdaq index climbed 0.9%, the Dow Jones index rose 0.3%, and the S&P 500 increased 0.6% on Wall Street.Fineos  said that its customer cash receipts, net of tax, of 31.5 million euros for the three months ended Sept. 30 were 11% lower than the year-ago period due to different year-on-year payment cycles from some large customers. It appointed Chief Executive Michael Kelly as executive chairman, effective Jan. 1, 2026, succeeding Anne O'Driscoll.On the flip side, the healthcare sector was down almost 1%.Lumos Diagnostics  Chair Sam Lanyon said the company's strategy remains centered on the global commercialization of its point-of-care FebriDx diagnostic test and that in the US, six of seven Medicare Administrative Contractors can provide full reimbursement per test.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7016","LU0128526141.USD","LDX.AU","BK4585","BK4581","BK7126","BK4134","XLV","III","XBI","BK4588","HCSG","LABU","FCL.AU","LU0029874061.USD","BK4137"],"gpt_icon":0},{"id":"2577633328","title":"BUZZ-Australia's Lumos Diagnostics hits 3-1/2-year high on sales jump","url":"https://stock-news.laohu8.com/highlight/detail?id=2577633328","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577633328?lang=en_us&edition=fundamental","pubTime":"2025-10-23 11:21","pubTimestamp":1761189694,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Lumos Diagnostics hits 3-1/2-year high on sales jump** Shares of Lumos Diagnostics LDX.AX rise as much as 12.8% to A$0.265, highest level since May 12, 2022** Q1 product revenue rises four-fold to $1.2 million, helped by increasing adoption of FebriDx across the U.S.** FebriDx is co's rapid point of care test to help differentiate between bacterial and non-bacterial acute respiratory infections** YTD, shares have risen more than seven-fold in value   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nL6N3W405L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7126","LDX.AU"],"gpt_icon":0},{"id":"2577344113","title":"BRIEF-Lumos Diagnostics Reports Q1 Revenue Of $3.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2577344113","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577344113?lang=en_us&edition=fundamental","pubTime":"2025-10-23 09:32","pubTimestamp":1761183142,"startTime":"0","endTime":"0","summary":"BRIEF-Lumos Diagnostics Reports Q1 Revenue Of $3.4 MillionOct 23 (Reuters) - Lumos Diagnostics Holdings Ltd LDX.AX:QUARTERLY ACTIVITIES/APPENDIX 4C CASH FLOW REPORTREPORTS Q1 REVENUE OF $3.4 MILLIONFurther company coverage: LDX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUE7VWC80:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7126","LDX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}]}}